Key Drivers
- Strong margins
- Robust cash flow
- High leverage
AIAI Summary
BMY should be viewed as a cash-generative transition story rather than a broken legacy-pharma name: strong margins and free cash flow support the dividend and R&D, but the stock likely stays range-bound until newer launches and pipeline assets clearly outgrow patent-cliff declines, making execution the decisive catalyst.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Robust cash flow
- •High leverage
BMY shows strong profitability and cash generation with solid returns, but elevated leverage and large intangibles keep the balance sheet and dividend sustainability as the key risks.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Reclaim needed
BMY has trended lower over the last month, but the $55.67-$56.00 support zone is still holding; a break below $55.67 would weaken the setup, while a move back above $58.2 would signal stabilization.
Failed rally to $60.59, then lower highs and lower lows into mid-May
Sentiment & News
Key News Insights:
- •Earnings beat
- •Pipeline growth
- •Legacy pressure
Bristol Myers is delivering solid near-term earnings and portfolio growth, but still faces legacy-drug decline and patent-expiry pressure that could limit longer-term revenue.
Near-term execution and valuation support the stock, but sustained upside depends on pipeline conversion outpacing legacy revenue declines
Similar Companies in Healthcare
Other companies in the same sector with AI ratings